Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M108291200 on October 8, 2001

J. Biol. Chem., Vol. 276, Issue 50, 46870-46877, December 14, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/50/46870    most recent
M108291200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jiang, J. L.
Right arrow Articles by Chan, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jiang, J. L.
Right arrow Articles by Chan, H. C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Involvement of HAb18G/CD147 in Regulation of Store-operated Calcium Entry and Metastasis of Human Hepatoma Cells*

Jian Li JiangDagger §, Qing ZhouDagger , Mei Kuen YuDagger , Lok Sze HoDagger , Zhi Nan Chen§, and Hsiao Chang ChanDagger

From the Dagger  Epithelial Cell Biology Research Center, Department of Physiology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong and the § Cell Engineering Research Center, The Fourth Military Medical University, Xi'an 710032, China

Received for publication, August 28, 2001, and in revised form, October 5, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The present study examined the effect of hepatoma-associated antigen HAb18G (homologous to CD147) expression on the NO/cGMP-regulated Ca2+ mobilization and metastatic process of human hepatoma cells. HAb18G/CD147 cDNA was transfected into human 7721 hepatoma cells to obtain a cell line stably expressing HAb18G/CD147, T7721, as demonstrated by Northern blot and immunocytochemical studies. 8-Bromo-cGMP (cGMP) inhibited the thapsigargin-induced Ca2+ entry in a concentration-dependent manner in 7721 cells. The cGMP-induced inhibition was abolished by an inhibitor of protein kinase G, KT5823 (1 µM). However, expression of HAb18G/CD147 in T7721 cells decreased the inhibitory response to cGMP. A similar concentration-dependent inhibitory effect on the Ca2+ entry was observed in 7721 cells in response to a NO donor, (±)-S-nitroso-N-acetylpenicillamine (SNAP). The inhibitory effect of SNAP on the thapsigargin-induced Ca2+ entry was significantly reduced in HAb18G/CD147-expressing T7721 cells, indicating a role for HAb18G/CD147 in NO/cGMP-regulated Ca2+ entry. Experiments investigating metastatic potentials demonstrated that HAb18G/CD147-expressing T7721 cells attached to the Matrigel-coated culture plates and invaded through Matrigel-coated permeable filters at the rate significantly greater than that observed in 7721 cells. Both the attachment and invasion rates could be suppressed by SNAP, and the inhibitory effect of SNAP could be reversed by NO inhibitor, NG-nitro-L-arginine methyl ester. The sensitivity of the attachment and invasion rates to cGMP was significantly reduced in T7721 cells as compared with 7721 cells when cells were pretreated with thapsigargin. The difference in the sensitivity between the two cells could be abolished by a Ca2+ channel blocker, Ni2+ (3 mM). These results suggest that HAb18G/CD147 enhances metastatic potentials in human hepatoma cells by disrupting the regulation of store-operated Ca2+ entry by NO/cGMP.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

HAb18G is a new hepatoma-associated antigen recently cloned by hepatoma monoclonal antibody HAb18 screening from human hepatocellular carcinoma cDNA library (1). HAb18G is abundantly expressed in human hepatoma tissues and on the cell surface of several highly metastatic hepatoma cell lines as detected by immunohistochemistry using monoclonal antibody against HAb18G (2-4). HAb18G is a highly glycosylated transmembrane protein of 60 kDa with an ectodomain consisting of two regions exhibiting the characteristics of the immunoglobulin superfamily (1). The amino acid sequence of HAb18G is identical to that of CD147, which has recently generated a great deal of interest (5). Other names for CD147 include human basigin, extracellular matrix metalloproteinase inducer (EMMPRIN),1 and human leukocyte activation-associated M6 antigen (6-9). Homologues in other species include rat OX-47 antigen, mouse basigin or gp42, chicken HT7 molecules, and rabbit homologue (10, 11). A role for CD147 as an adhesion molecule has been proposed, and it has been reported to bind to a variety of cell types including endothelial cells and fibroblasts (5).

Our previous studies have demonstrated that HAb18G stimulates fibroblast cells to produce elevated levels of several matrix metalloproteinases (MMPs) (1), including MMP-1, MMP-2, and MMP-9, which are well known for prompting invasion of hepatoma cells (12-14). Lim et al. found that EMMPRIN up-regulated MMP-1 mRNA expression, which was dependent on tyrosine kinase activity (15). However, substrates or ligands for CD147 or enzymes that modify CD147 are still not known. It is not clear whether CD147 (or HAb18G, basigin, EMMPRIN, M6, etc.) is directly involved in cell adhesion or as an adhesion signal transmitting molecule or a regulator of adhesion.

The process of proliferation, invasion, and metastasis is a complex one that involves both the autonomy of the malignant cells and their interaction with the cellular and extracellular environments. The way in which tumor cells respond to cellular and extracellular stimuli is regulated through transduction of those signals and translation into cellular activities. A frequent common denominator of the different signal transduction pathways is cellular Ca2+ mobilization. Ca2+ has been shown to play a role in the regulation of proliferation, invasion, and metastatic potential (16-18). The motility and adhesion properties of several normal cell types have been shown to work through G protein-sensitive pathways, suggesting that this type of cell signaling may be involved in tumor invasion and metastasis (19-21). Extracellular matrix components, such as laminin, collagen type IV, fibronectin, and thrombospondin, also have been shown to stimulate tumor cell migration (22-27). Ca2+ appears to play a pivotal role in extracellular matrix-induced tumor cell migration as demonstrated in the A2058 human melanoma cells stimulated with type IV collagen and fibronectin (24, 28, 29).

Ca2+ release from internal stores by either inositol trisphosphate (IP3) (e.g. with cholinergic agonists like carbachol) or by inhibition of the Ca2+ pump in the internal store (e.g. with thapsigargin or cyclopiazonic acid) stimulates a Ca2+ influx in nonexcitable cells, often referred to as "store-operated" or "capacitative" Ca2+ entry (30). Several factors have been reported to modulate this Ca2+ entry, including small molecular weight G protein(s), serine/threonine phosphatase, tyrosine kinase or phosphatase, cAMP, NO, and guanosine 3',5'-cGMP (31-34). Among these, NO and cGMP have received much attention recently. It has been proposed that NO and cGMP may play a key role in regulating Ca2+ entry into pancreas acinar cells (35, 36). It was shown that the Ca2+ content of the internal stores apparently regulated NOS activity and subsequently NO and cGMP, which had a biphasic effect on restoring Ca2+ entry after it had been blocked by NOS/guanylate cyclase inhibitors. These experiments indicated that store-operated Ca2+ entry was regulated tightly by [cGMP]i. Negative regulation of store-operated Ca2+ entry by cGMP via a protein kinase G-dependent mechanism has also been observed recently in other cell types including endothelial cells (34). Thus, cGMP appears to play an absolutely crucial role in regulating store-operated Ca2+ entry. However, very little is known about the physiological importance of store-operated Ca2+ entry in tumor cells, and virtually nothing is known about the intracellular regulation of store-operated Ca2+ entry involved in the process of cancer metastasis, although NO has been implicated in cancer metastasis through Ca2+-dependent mechanisms involving different MMPs (37).

We have recently demonstrated the presence of a NO-cGMP-regulated store-operated Ca2+ entry pathway in human hepatoma 7721 cells (38). In contrast to other highly metastatic hepatoma cells, 7721 cells have been shown to have lower metastatic activities and do not express HAb18G (2-4). It appears that the expression of HAb18G is associated with high metastatic potencials of human hepatoma cells. The present study further explored the involvement of HAb18G/CD147 in regulating the Ca2+ entry signaling pathway and metastatic potentials by stably transfecting HAb18G into 7721 cells. We found that the expression of HAb18G/CD147 reduced the sensitivity of the store-operated Ca2+ entry to NO/cGMP and enhanced the metastatic potentials of human hepatoma cells.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- 8-Br-cGMP, (±)-S-nitroso-N-acetylpenicillamine (SNAP), NG-nitro-L-arginine methyl ester (L-NAME) and thapsigargin were obtained from Calbiochem (La Jolla, CA). RPMI 1640, fetal bovine serum, Geneticin (G418 sulfate), and Lipofectin transfection reagents were purchased from Life Technologies, Inc. Fura2/AM was obtained from Molecular Probes, Inc. (Eugene, OR). TRIZOL for total RNA isolation was from Life Technologies, Inc., and ExpressHybTM hybridization solution for Northern blot was from CLONTECH Laboratories, Inc. (Palo Alto, CA). All restriction endonucleases were purchased from Promega Corporation (Madison, WI), and [32P]dCTP was from Amersham Pharmacia Biotech. Fluorescein isothiocyanate-conjugated rat anti-mouse IgG and Matrigel were obtained from Becton Dickinson Labware (Bedford, MA). Other reagents were from Sigma.

Cell Culture-- The human 7721 hepatoma cells (obtained from the Institute of Cell Biology, Academic Sinica) were cultured with RPMI 1640 medium supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 2% L-glutamin at 37 °C in a humidified atmosphere of 5% CO2.

Transfection Experiment and Northern Blot Analysis of the Expression-- The expression vector pcDNA3-HAb18G was made in our laboratory. The human 7721 hepatoma cells were seeded onto 35-mm plates at a density of 1 × 105/plate. After cells were grown to 60-80% confluency, transfection was performed using Lipofectin transfection reagent according to the manufacturer's instructions. Briefly 2 µg of expression plasmid DNA and 15 µl of Lipofectin transfection reagent in RPMI 1640 serum and antibiotic-free medium were incubated together for 45 min at room temperature to allow liposome-DNA complexes to form. The cells were washed and incubated with serum and antibiotic-free medium after the addition of liposome-DNA complexes for 8 h. The transfection solution was removed, and fresh medium with serum was added and incubated for another 48 h. Medium supplemented with G418 (400 µg/ml) was added to the cells. The G418 selection medium was changed every 2-3 days, until Lipofectin-treated control cells died. After a 3-week culture in selection medium, the cells were cloned by clonal dilution.

Total RNA was isolated from cells using trizol Reagent, and 20 µg was resolved on 1% agarose/formaldehyde gels and transferred to nitrocellulose membranes. Hybridization was done using HAb18G cDNA fragment as the probe in ExpressHybTM hybridization solution according to the manufacturer's instructions. The membranes were exposed to autoradiographic film for up to 2 days.

Immunocytochemistry-- Human hepatoma monoclonal antibody HAb18 was produced and characterized in our laboratory (39). 7721 and HAb18G-transfected T7721 cells were seeded onto sterile glass coverslips in 15-cm cell culture dishes. Following attachment, coverslips were washed in PBS and then held in 100% methanol at -20 °C for 30 min. Methanol was removed, and the cells were immunostained. All further processing was carried out at room temperature. For immunostaining, the cells were rehydrated in PBS for 5 min and then were held in blocking solution (1% bovine serum albumin in PBS) for 1 h. The coverslips were rinsed briefly in PBS, incubated in a solution of the primary antibody HAb18 (1 µg/ml in blocking solution) for 1 h, and subjected to four 5-min PBS washes. The cells were then incubated with rat anti-mouse IgG-fluorescein isothiocyanate at 3 µg/ml in blocking solution for 1 h. Following five 5-min washes in PBS, coverslips were mounted in glycerol:water solution (v/v, 1:1) on glass slides. Fluorescence microscopy was taken on.

Measurement of Intracellular Free Calcium Concentration-- [Ca2+]i was measured using Fura2/AM. The cells were loaded with the dye by incubation with 5 µM Fura2/AM for 45 min in dark at 37 °C in normal PBS (NPBS) containing 2 mM CaCl2, pH 7.4. The cells were then washed and resuspended in NPBS. To start the experiment, the cells were pretreated with 4 µM thapsigargin for 20 min. Then the cells were washed with and maintained briefly in PBS containing no Ca2+ and 2 mM EGTA. Unless stated otherwise, the cells were pretreated with or without chemicals (i.e. 8-Br-cGMP or NiCl2) for 5 min. The fluorescent signal was monitored and recorded by an LS-50B luminescent spectrometer (Perkin Elmer). The excitation light at 340 and 380 nm was provided by a 150 W Xenon arc lamp (Perkin Elmer) and a filter wheel (Perkin Elmer) containing 340- and 380-nm interference filters (Perkin Elmer). The emitted fluorescence at 510 nm was collected by a photomultiplier tube and recorded.

Cell Adhesion Assay-- The wells of the 96-well culture plate were coated with Matrigel at a concentration of 5 µg/ml and incubated at 4 °C overnight. The coated wells were blocked with PBS containing 2% bovine serum albumin for 30 min and then washed with PBS. Cells suspension in serum-free medium containing 0.1% bovine serum albumin was added to the wells (2 × 104/well) and incubated at 37 °C, 5% CO2 for 30-60 min with or without test agents (i.e. 8-Br-cGMP, SNAP, or L-NAME). After removing medium and nonattached cells, 0.2% crystal violet was added for 10 min. The plate was gently washed with tap water and dried in air for 24 h. 0.1 ml of 5% SDS with 50% ethanol was added for 20 min, and then the plate was read at 540 nm.

Cell Migration Assay-- The chemotactic cell migration assay was performed using 24-well transwell units (COSTAR Corning Inc.) with an 8-µm pore size polycarbonate filter according to the method described by Mensing et al. (40). Each lower compartment of the transwell contained 600 µl of 0.5% fetal bovine serum as chemoattractant or 0.5% bovine serum albumin as negative control in RPMI 1640. Cells (1 × 105) in 0.1 ml of RPMI 1640 containing 0.1% bovine serum albumin were added into the upper compartment of the transwell unit and incubated for 6 h at 37 °C in a humidified atmosphere containing 5% CO2. After removing the cells from the upper surface of the membrane with a swap, cell numbers on the underside were determined using colorimetric crystal violet assay.

Invasion Assay-- The procedure for the chemotactic cell invasion test was the same as in the chemotactic cell migration assay, except that the upper side of polycarbonate filter was coated with Matrigel (5 µg/ml in cold medium) to form a continuous thin layer. Prior to the addition of cell suspension, the dried layer of Matrigel matrix was rehydrated with medium without fetal bovine serum for 2 h at room temperature, and the incubating time varied with a maximum of 72 h. Agents such as 8-Br-cGMP or SNAP were added in the upper compartment after the addition of cell suspension. When thapsigargin treatment assay was carried out, the cells were incubated with 4 µM thapsigargin for 20 min prior to addition of cell suspension. The cells remaining in the upper compartment were completely removed with gently swabbing. The number of cells invaded through the filter into the lower compartment was determined using colorimetric crystal violet assay.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Stable Transfection of HAb18G into Human Hepatoma Cells-- We have demonstrated in previous studies that store-operated Ca2+ entry in human 7721 hepatoma cells was negatively regulated by NO/cGMP (38). To examine the effect of HAb18G, we transfected HAb18G cDNA into human 7721 hepatoma cells and cloned after G418 selection in the present study. A hepatoma cell line stably expressing HAb18G was obtained and named T7721. The expression of HAb18G in T7721 but not 7721 cells was demonstrated by Northern blot (Fig. 1A) and immunocytochemistry (Fig. 1B).


View larger version (67K):
[in this window]
[in a new window]
 
Fig. 1.   Stable transfection of HAb18G into human hepatoma cells. A, Northern blot analysis of HAb18G mRNA lever in 7721 and T7721 cells. Total RNA was isolated and fractionated on a 1% agarose gel containing 0.22 M formaldehyde and transferred by capillary blotting and cross-linked to a nitrocellulose membrane. The blot was then probed with 32P-labeled HAb18G cDNA. The results demonstrate expression of HAb18G mRNA in a transfected T7721 cell line. B, immunocytochemical demonstration of expression of HAb18G. 7721 and T7721 cells were fixed and stained with monoclonal antibody HAb18, followed by fluorescein isothiocyanate-conjugated rat anti-mouse IgG antibody. T7721 cells were positive by staining. Left panels, fluorescence photomicrograph; right panels, phase contrast photomicrograph.

Thapsigargin-induced Store-operated Ca2+ Entry-- Thapsigargin, a potent inhibitor of endoplasmic reticulum Ca2+-ATPase, was used to deplete intracellular Ca2+ stores and induce Ca2+ entry from extracellular space. After treatment with 4 µM thapsigargin in Ca2+-free and 2 mM EGTA-containing medium for 20 min, the addition of 2 mM CaCl2 induced a rise in [Ca2+]i because of Ca2+ entry (Fig. 2). The thapsigargin-induced elevation of [Ca2+]i was completely blocked by Ni2+ (3 mM), a potent blocker of Ca2+ entry that competes for Ca2+-binding sites (41), in both 7721 cells and T7721 cells (Fig. 2), confirming the presence of the store-operated Ca2+ entry in both cell types.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of Ni2+ on thapsigargin-induced rise in [Ca2+]i. [Ca2+]i was monitored in a Fura2/AM-loaded human hepatoma cell line. The cells were incubated in NPBS with 4 µM thapsigargin for 20 min and then resuspended in calcium-free PBS. Ni2+ was introduced 5 min prior to the measurement. At the time indicated by the arrow, the media were changed to the respective media containing 2 mM CaCl2 without EGTA. A, 7721 cells. B, T7721 cells.

Effect of HAb18G on NO/cGMP-sensitive Store-operated Ca2+ Entry-- cGMP, an activator of PKG, has been shown to regulate the store-operated Ca2+ entry (34, 36). The present study examined the effect of 8-Br-cGMP on the store-operated Ca2+ entry in both human 7721 and T7721 hepatoma cells. Fig. 3 shows that application of 8-Br-cGMP reduced the thapsigargin-induced [Ca2+]i rise in 7721 cells in a concentration-dependent manner. 2 mM 8-Br-cGMP almost completely inhibited the Ca2+ entry with 96.9 ± 1.9% inhibition (Fig. 3, A and C). The cGMP-induced inhibition was reversed by a specific PKG inhibitor, KT5823 (1 µM) (Fig. 4). However, the inhibitory effect of 8-Br-cGMP on the thapsigargin-induced [Ca2+]i rise was significantly attenuated in HAb18G-expressing T7721 cells with only 25.3 ± 13.1% inhibition observed at 2 mM 8-Br-cGMP (Fig. 3, B and C).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   A dose-dependent inhibition effect of 8-Br-cGMP on thapsigargin-induced Ca2+ influx in hepatoma cells. The cells were incubated in NPBS with 4 µM thapsigargin for 20 min. 8-Br-cGMP at the concentrations indicated below the record was introduced 5 min prior to the measurement. At the time indicated by the arrow, 2 mM CaCl2 was added into the medium. A, 7721 cells. B, T7721 cells. C, concentration-dependent inhibition by 8-Br-cGMP on thapsigargin-induced Ca2+ entry in hepatoma cells (7721 and T7721 cells). The values are the percentages of change from base line, and they are expressed as the means ± S.E. (n = 4-6).


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of PKG inhibitor on thapsigargin-induced Ca2+ influx.. The Ca2+ entry fluorescence ratios shown were obtained in cells without chemical treatment (control) or treated with 2 mM 8-Br-cGMP (cGMP) or both cGMP and 1 µM KT5823 (cGMP/KT5823). The cells were incubated in NPBS with 4 µM thapsigargin for 20 min. 2 mM 8-Br-cGMP or plus 1 µM KT5823 was introduced 5 min prior to the measurement. 1 mM CaCl2 was introduced to the medium to obtain the fluorescent signal of Ca2+ entry. The values are the means ± S.E. (n = 4-6).

NO is an important intracellular signal molecule that activates soluble guanylye cyclase to synthesize cGMP (42). The present study was carried out to investigate the involvement of NO in regulation of the store-operated Ca2+ entry using a NO donor, SNAP, to trigger production of endogenous cGMP. Similar to the effect of 8-Br-cGMP, SNAP inhibited the thapsigargin-indued Ca2+ influx in a concentration-dependent manner (Fig. 5), and the inhibitory response in 7721 was significantly greater than that observed in HAb18G-expressing T7721 cells, 48.3 ± 12.5% as compared with 19.8 ± 4.1% inhibition observed at 100 µM SNAP, respectively (p < 0.01; Fig. 5).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 5.   Concentration-dependent inhibition by SNAP on the thapsigargin-induced Ca2+ entry in hepatoma cells. Intracellular Ca2+ concentration was presented by fluorescence ratio of Fura2. The cells were incubated in NPBS with 4 µM thapsigargin for 20 min and resuspended in calcium-free PBS. 2 mM CaCl2 was introduced to the medium to obtain the fluorescent signal of Ca2+ entry. The values are the means ± S.E. (n = 4-6).

Effect of HAb18G on Metastatic Processes-- HAb18G/CD147 is a potential adhesion molecule that has been shown to stimulate expression and release of MMPs through some kinase signaling pathways (1, 15, 43). It is now widely acknowledged that some MMPs (such as MMP-2 and MMP-9) are regulated by NO-cGMP-Ca2+ signaling pathways (37, 44, 45). The present study tested the involvement of HAb18G and NO in regulating metastatic potentials of the human hepatoma cells by examining cell adhesion, migration, and invasion processes in vitro.

We used Matrigel-coated plates and chambers as models for investigation of possible signaling pathways involved in extracellular matrix-induced metastatic processes. Matrigel is a solubilized basement membrane preparation containing almost all of the extracellular matrix components (46). The following studies were carried out with Matrigel as adhesion substratum. Fig. 6A shows that after 30 min of incubation, a significant increase in the amount of cells attached to the Matrigel-coated plates, expressed as fractions of total seeded cells, was observed in HAb18G/CD147-expressing T7721 cells (53.4 ± 1.8%) as compared with 7721 cells (34.6 ± 0.6%, p < 0.001).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 6.   Adhesion and migration potentials of human 7721 hepatoma cells and HAb18G-transfected T7721 cells to Matrigel. A, adhesion assay. The cells were suspended in serum-free medium and seeded into the Matrigel (5 µg/ml)-coated wells. After the incubation for 30 min at 37 °C, the percentage of adhered cells was determined by using the colorimetric crystal violet assay. The values are the means ± S.E. (n = 6-8). B, migration assay. The amount of migrated cells was determined in Transwell chambers as described under "Experimental Procedures." The values were presented as the means ± S.E. (n = 3-4).

We used Transwell chambers to investigate cell migration. The ability of HAb18G/CD147-expressing T7721 cells to migrate from one compartment to the other in the Transwell chambers (without Matrigel) was significantly greater than that of 7721cells, 36.4 ± 0.6% as compared with 19.8 ± 1.1% after 36 h, respectively (p < 0.001; Fig. 6B)

The Transwell chambers were also coated with Matrigel to assay for the ability of cells to invade through the reconstructed basement membrane. As depicted in Fig. 7, at various time intervals, the invasive potential, measured as fractions of total seeded cells invaded through the membrane, of HAb18G/CD147-expressing T7721 cells was significantly greater than that observed in 7721 cells (p < 0.05).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 7.   The time course change of the invasive potential of human 7721 hepatoma cells and HAb18G-transfected T7721 cells (36-72 h). The invasive potential was evaluated in Transwell chambers as described under "Experimental Procedures." The values were presented as the means ± S.E. (n = 3-4).

Involvement of NO/cGMP in Metastatic Processes-- We investigated the possible involvement of NO/cGMP in cell adhesion and invasion processes. Pretreatment of SNAP (200 µM) for 30 min significantly reduces the fraction of attached cells in both 7721 and T7721 cells by 34.6 ± 1.2 and 34.4 ± 5.0%, respectively (p > 0.05), and L-NAME (100 µM), a NOS blocker, reversed the effect of SNAP (Fig. 8). Invasion assay also showed that the fraction of cells invaded through Matrigel-coated filter was decreased by treatment with 8-Br-cGMP (2 mM) in both 7721 (31.1 ± 8.2%) and T7721 (17.6 ± 2.1%) (p < 0.05). These results indicated that NO/cGMP may be involved in the metastatic processes of hepatoma cells.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 8.   Effects of SNAP and L-NAME on cell adhesion to Matrigel. The cells were suspended in serum-free medium supplemented with 200 µM SNAP or together with 200 µM L-NAME and seeded into the Matrigel (5 µg/ml)-coated wells. After incubation for 30 min at 37 °C, the percentage of adhered cells was determined using colorimetric crystal violet assay. A, 7721 cells. B, T7721 cells. The values are the means ± S.E. (n = 6-8).

The Involvement of NO/cGMP-sensitive Ca2+ Entry in Metastatic Processes-- As shown above, the store-operated Ca2+ entry was negatively regulated by NO/cGMP, and the sensitivity of the store-operated Ca2+ entry in T7721 cells to NO/cGMP was significantly reduced as compared with that in 7721 cells. However, although both cell attachment and invasive ability was significantly inhibited by either NO or cGMP, there seemed to be no significant difference between the two cell types in the sensitivity of their metastatic potentials to NO/cGMP treatment. (The inhibition rates on invasion were 13.0 ± 1.7 and 11.0 ± 1.4% in 7721 and T7721, respectively; p > 0.05.) Further experiments were performed using thapsigargin to elicit store-operated Ca2+ entry. In the presence of thapsigargin (4 µM), the cGMP-induced inhibition of cell invasion observed in 7721 cells was significantly greater than that observed in HAb18G-expressing T7721 cells, 26.2 ± 3.1 and 16.7 ± 3.1%, respectively, p < 0.05. This was consistent with the earlier Ca2+ measurements showing greater sensitivity of the thapsigargin-induced Ca2+ entry in 7721 cells to NO/cGMP as compared with T7721 cells.

The possible involvement of the NO/cGMP-sensitive Ca2+ entry in cell attachment and invasion was further demonstrated using Ni2+. After treatment with Ni2+ (3 mM), the fraction of cells attached was 58.7 ± 2.6 and 60.9 ± 5.0% in 7721 and T7721 cells, respectively (p > 0.05). Similarly, Ni2+ treatment resulted in 14.4 ± 1.0 and 13.8 ± 1.1% cells invaded in 7721 and T7721 cells, respectively (p > 0.05). Taken together, the difference in metastatic potential (i.e. attachment and invasion) between 7721 and T7721 cells was abolished by blocking the Ca2+ entry with 3 mM Ni2+. Those results suggest that the HAb18G-induced difference in metastatic potentials involved Ca2+ entry.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Invasion and metastasis are complicated and fatal cascades in human hepatoma, but the underlying molecular mechanisms involved remain largely unknown. Previous studies have implicated a hepatoma-associated antigen, HAb18G (also named CD147 and EMMPRIN), in metastasis (1, 9, 15). The present study has further demonstrated the involvement of HAb18G in the modulation of NO/cGMP-sensitive store-operated Ca2+ entry and metastatic potentials of human hepatoma cells. This has been made possible by using a cell line stably expressing HAb18G obtained by transfection of HAb18G into the human hepatoma 7721 cell line, which has been shown to possess a low metastatic rate (47) and a NO/cGMP-sensitive store-operated Ca2+ entry pathway (38).

The present results have clearly demonstrated that the expression of HAb18G attenuates the sensitivity of store-operated Ca2+ entry to NO/cGMP in the hepatoma cells. Although the thapsigargin-induced store-operated Ca2+ entry appears to be the same in both 7721 and HAb18G-expressing T7721 cells, as evidenced by the magnitude of the Ca2+ entry and its blockage by Ni2+, the sensitivity of the Ca2+ entry to cGMP or the NO donor, SNAP, was significantly different in the two cell types. cGMP or SNAP inhibits the thapsigargin-induced Ca2+ entry in a concentration-dependent manner in 7721 cells, and this effect of cGMP can be reversed by highly specific PKG inhibitor, indicating a negative regulatory mechanism involving NO/cGMP via PKG-dependent pathway. The sensitivity of the thapsigargin-induced Ca2+ entry to either cGMP or SNAP was greatly attenuated in the HAb18G-expressing T7721 cells, suggesting that the negative regulation of the Ca2+ entry by NO/cGMP could be opposed by the expression of HAb18G.

It is well known that Ca2+ plays a role in the regulation of proliferation, invasion, and metastatic potentials (17, 37, 48-50). However, very little is known about the significance of the store-operated Ca2+ entry and its regulation in the process of cancer metastasis. The present study has demonstrated the possible involvement of the NO/cGMP-sensitive store-operated Ca2+ entry and a possible role of HAb18G in metastatic processes in human hepatoma cells. The present results obtained from assays for cell adhesion, migration, and invasion processes involved in metastasis indicated a greater metastatic potential of the HAb18G-expressing T7721 cells as compared with that of 7721 cells. This was evidenced by the observation that for a given period of time, the fraction of cells attached to or invaded through Matrigel substrate or migrated from one compartment to the other across Transwell filter in the HAb18G-expressing T7721 cells was significantly greater than that in 7721 cells. The fact that cell attachment and invasion could be greatly inhibited by Ni2+ suggests that Ca2+ entry plays a role in these processes. Furthermore, the observed difference in the attachment and invasive ability between the two cell types was also abolished by Ni2+ indicates that the greater metastatic potential induced by HAb18G expression may be through a mechanism involving Ca2+ entry.

One of the interesting observations is that cell attachment and invasion in both cell types could be inhibited by either cGMP or SNAP, whose effect could be reversed by a NO synthase inhibitor, suggesting the involvement of NO/cGMP in the metastatic processes. However, there was no significant difference between the two cell types in the sensitivity of their metastatic potentials to cGMP or SNAP treatment. This would first tend to suggest that the effect of HAb18G expression exerted directly or indirectly on the metastatic potentials did not involve NO/cGMP. However, when cells were pretreated with thapsigargin to empty the intracellular Ca2+ store, which is expected to elicit store-operated Ca2+ entry, a significantly greater inhibition of cell invasion by cGMP in 7721 cells was then observed as compared with that in HAb18G-expressing T7721 cells. These results suggest that metastatic potentials in human hepatoma cells depend on the Ca2+ homeostasis in the cells and that NO/cGMP and HAb18G may play opposing roles in modulating the cellular Ca2+ homeostatic states, especially the store-operated Ca2+ entry. The abolishment of observed differences between the two cell types in their metastatic potentials by Ni2+ is consistent with the notion that Ca2+ entry, which is most likely to be NO/cGMP-sensitive, is involved in the mechanism by which HAb18G influences the metastatic potentials of the hepatoma cells. It should be noted that the present results do not exclude the possible involvement of HAb18G in inducing Ca2+ release from the intracellular store, thus contributing to the metastatic potentials of the hepatoma cells. The fact that a significant difference in the cGMP-induced inhibitory effect on cell invasion between 7721 and T7721 cells was only observed after treatment with thapsigargin, which affects intracellular Ca2+ store as well as promotes Ca2+ entry, suggests that the intracellular Ca2+ store or the intracellular Ca2+ homeostatic state is critical for the determination of HAb18G-dependent and NO/cGMP-sensitive metastatic potentials. It is not clear from the present study whether HAb18G is directly involved in modulating the intracellular Ca2+ homeostatic state. What is clear, however, from the present results obtained from both the Ca2+ measurements and the metastatic potential assays is that the negative regulation of Ca2+ entry by NO/cGMP can be inhibited by HAb18G expression, which appears to influence the metastatic potentials of the hepatoma cells.

The present finding is consistent with previous results from various laboratories demonstrating a role for HAb18G/CD147 in cancer metastasis (1, 51, 52). The immediate question followed is how HAb18G/CD147 affects the metastatic potentials of tumor cells via NO/cGMP-sensitive Ca2+ entry. Many reports have indicated that Ca2+ is involved in cancer metastasis by regulating expression and/or release of MMPs (37, 45, 49, 53). MMPs have been implicated in several aspects of tumor progression, including invasion through basement membrane and interstitial matrices, angiogenesis, and tumor cell growth (12-14). The release of MMPs appears to be regulated by intracellular Ca2+, although it is still unresolved whether intracellular Ca2+ store or Ca2+ entry plays a major role (37, 54, 55). Tumor-derived NO has also been reported to promote the invasiveness of certain human and animal tumors, and the increased invasiveness resulted from alterations in the balance in the production of MMPs and their natural inhibitors (tissue inhibitors of metalloproteinase) (56). Together with our previous observation that HAb18G stimulates production of several MMPs from fibroblasts (1), the present results suggest a possible link between HAb18G and metastatic potentials through NO/cGMP and Ca2+ entry and MMPs. Like in many other cells, it appears that the Ca2+ entry in the hepatoma cells is normally safeguarded by NO/cGMP. However, the expression of HAb18G/CD147 may disrupt the Ca2+ entry regulation by NO/cGMP, thus allowing greater Ca2+ influx into the cells, leading to greater production and/or release of MMPs and, therefore, enhanced metastatic potentials. This may explain why HAb18G/CD147 is abundantly expressed in several highly metastatic cancer cells (2-4, 57, 58).

However, it remains to be elucidated how the expression of HAb18G/CD147 leads to attenuation of the response of store-operated Ca2+ entry to NO/cGMP and thus enhanced metastatic potentials. It is possible that HAb18G/CD147 may up-regulate or down-regulate the expression of cellular factors that are related to the NO/cGMP-sensitive pathway. For example, down-regulation of PKG may render the store-operated Ca2+ entry insensitive to NO/cGMP. On the other hand, overexpression of Ca2+ channels that are responsible for store-operated Ca2+ entry may also reduce the effectiveness of NO/cGMP to control the Ca2+ entry, considering that more NO/cGMP would be required to shut down these overexpressed Ca2+ channels. The investigation of these possibilities is currently underway in our laboratory.

In summary, the present studies have provided evidence indicating that store-operated Ca2+ entry in human hepatoma cells is negatively regulated by NO/cGMP via PKG-dependent pathway and that this regulation is opposed by the expression of HAb18G/CD147. The present results have also suggested that the expression of HAb18G/CD147 may enhance the metastatic potentials in human hepatoma cells by disrupting the regulation of the Ca2+ entry by NO/cGMP.

    FOOTNOTES

* The work was supported by National 863 Funding Scheme of China and Strategic Program of the Chinese University of Hong Kong.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Epithelial Cell Biology Research Center, Dept. of Physiology, Faculty of Medicine, Chinese University of Hong Kong, Shatin, NT, Hong Kong. Tel.: 852-2609-6839; Fax: 852-2603-5022; E-mail: hsiaocchan@cuhk.edu.hk.

Published, JBC Papers in Press, October 8, 2001, DOI 10.1074/jbc.M108291200

    ABBREVIATIONS

The abbreviations used are: EMMPRIN, extracellular matrix metalloproteinase inducer; PKG, protein kinase G; Br, bromo; PBS, phosphate-buffered saline; NPBS, normal phosphate-buffered saline; SNAP, S-nitroso-N-acetylpenicillamine; L-NAME, NG-nitro-L-arginine methyl ester; MMP, matrix metalloproteinase; AM, acetoxylmethyl ester.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Chen, Z. N., Yang, Z., Mi, L., Jiang, J. L., and Guo, X. N. (1999) J. Cell. Mol. Immunol. 15, 34
2. Chen, Z. N. (1992) Chin. J. Oncol. 14, 9-12
3. Ji, Y. (1991) Chin. Med. J. 71, 369-372
4. Liu, Y. (1991) Chin. Med. J. 71, 362-365
5. Stockinger, H., Ebel, T., Hansmann, C., Koch, C., Majdic, O., Prager, E., Patel, D. D., Fox, A., Horejsi, V., Sagawa, K., and Shen, D. (1997) in Leukocyte Typing VI (Kishimoto, T. , Kikutani, H. , et al., eds) , pp. 760-763, Garland Publishing, New York
6. Kanekura, T., Miyauchi, T., Tashiro, M., and Muramatsu, T. (1991) Cell Struct. Funct. 16, 23-30[Medline] [Order article via Infotrieve]
7. Miyanuchi, T., Masuzawa, Y., and Muramatsu, T. (1991) J. Biochem. (Tokyo) 110, 770-774[Abstract/Free Full Text]
8. Kasinrerk, W., Fiebiger, E., Stefanova, I., Baumruker, T., Knapp, W., and Stockinger, H. (1992) J. Immunol. 149, 847-854[Abstract]
9. Biswas, C., Zhang, Y., Decastro, R., Guo, H., Nakamura, T., Kataoka, H., and Nabeshima, K. (1995) Cancer Res. 55, 434-439[Abstract/Free Full Text]
10. Fossum, S., Mallett, S., and Barclay, A. N. (1991) Eur. J. Immunol. 21, 671-679[Medline] [Order article via Infotrieve]
11. Seulberger, H., Unger, C. M., and Risau, W. (1992) Neurosci. Lett. 140, 93-97[CrossRef][Medline] [Order article via Infotrieve]
12. Arii, S., Mise, M., Harada, T., Furutani, M., Ishigami, S., Niwano, M., Mizumoto, M., Fukumoto, M., and Imamura, M. (1996) Hepatology 24, 316-322[CrossRef][Medline] [Order article via Infotrieve]
13. Ogata, R., Torimura, T., Kin, M., Ueno, T., Tateishi, Y., Kuromatsu, R., Shimauchi, Y., Sakamoto, M., Tamaki, S., Sata, M., and Tanikawa, K. (1999) Hum. Pathol. 30, 443-450[CrossRef][Medline] [Order article via Infotrieve]
14. Theret, N., Musso, O., Turlin, B., Lotrian, D., Bioulac-Sage, P., Campion, J. P., Boudjema, K., and Clement, B. (2001) Hepatology 34, 82-88[CrossRef][Medline] [Order article via Infotrieve]
15. Lim, M., Martinez, T., Jablons, D., Cameron, R., Guo, H., Toole, B., Li, J. D., and Basbaum, C. (1998) FEBS Lett. 441, 88-92[CrossRef][Medline] [Order article via Infotrieve]
16. Wasilenko, W. J., Palad, A. J., Somers, K. D., Blackmore, P. F., Kohn, E. C., Rhim, J. S., Wright, G. L., Jr., and Schellhammer, P. F. (1996) Int. J. Cancer 68, 259-264[CrossRef][Medline] [Order article via Infotrieve]
17. Cole, K., and Kohn, E. (1994) Cancer Metastasis Rev. 13, 31-44[CrossRef][Medline] [Order article via Infotrieve]
18. Clapham, D. E. (1995) Cell 80, 259-268[CrossRef][Medline] [Order article via Infotrieve]
19. Hauang, A. J., Manning, J. E., Banbak, T. M., Ratau, M. C., Hanser, K. R., and Silverstein, S. C. (1993) J. Cell Biol. 120, 1371-1380[Abstract/Free Full Text]
20. Marks, P. W., and Maxfield, F. R. (1990) J. Cell Biol. 110, 43-52[Abstract/Free Full Text]
21. Mamachi, T., Hirata, M., and Koga, T. (1986) Biochim. Biophys. Acta 889, 136-148[Medline] [Order article via Infotrieve]
22. Aznavoorian, S., stracke, M. L., Krutzsch, H., Schiffmann, E., and Liotta, L. A. (1990) J. Cell Biol. 110, 1427-1438[Abstract/Free Full Text]
23. McCarthy, J. B., Hagen, S. T., and Furcht, L. T. (1983) J. Cell Biol. 102, 179-188[Abstract/Free Full Text]
24. Savarese, D. M. F., Russel, J. T., Fatatis, A., and Liotta, L. A. (1992) J. Biol. Chem. 267, 21928-21935[Abstract/Free Full Text]
25. Zabrenetzsky, V., and Roberts, D. D. (1993) Proc. Am. Assoc. Cancer Res. 34, 33
26. Lester, B. R., Wein, L. S., McCarthy, J. B., Sun, Z., Smith, R. S., and Furcht, L. T. (1991) Int. J. Cancer 48, 113-120[Medline] [Order article via Infotrieve]
27. Lester, B. R., McCarthy, J. B., Sun, Z., Smith, R. S., Furcht, L. T., and Spiegel, A. M. (1989) Cancer Res. 49, 5940-5948[Abstract/Free Full Text]
28. Ray, J. M., and Stetler-Stevenson, W. G. (1995) EMBO J. 14, 908-917[Medline] [Order article via Infotrieve]
29. Alessandro, R., Masiero, L., Liotta, L. A., and Kohn, E. C. (1996) In Vivo 10, 153-160[Medline] [Order article via Infotrieve]
30. Putney, J., Jr. (1990) Cell Calcium 11, 611-624[CrossRef][Medline] [Order article via Infotrieve]
31. Moncada, S., Palmer, R. M. J., and Higgs, E. A. (1991) Pharmacol. Rev. 43, 109-142[Medline] [Order article via Infotrieve]
32. Bischof, G., Brenman, J., Bredt, D. S., and Machen, T. E. (1995) Cell Calcium 17, 250-262[CrossRef][Medline] [Order article via Infotrieve]
33. Kwan, H. Y., Huang, Y., and Yao, X. (2000) J. Biol. Chem. 275, 6758-6763[Abstract/Free Full Text]
34. Yao, X., Kwan, H. Y., Chan, F. C., Chan, N. W., and Huang, Y. (2000) FASEB J. 14, 932-938[Abstract/Free Full Text]
35. Gukovskaya, A., and Pandol, S. (1994) Am. J. Physiol. 266, G350-G356[Abstract/Free Full Text]
36. Xu, X., Star, R. A., Tortorici, G., and Muallem, S. (1994) J. Biol. Chem. 269, 12645-12653[Abstract/Free Full Text]
37. Wu, Y., Palad, A. J., Wasilenko, W. J., Blackmore, P. F., Pincus, W. A., Schechter, G. L., Spoonster, J. R., Kohn, E. C., and Somers, K. D. (1997) Clin. Cancer Res. 3, 1915-1921[Abstract]
38. Jiang, J. L., Yu, M. K., Chen, Z. N., and Chan, H. C. (2001) Cell Biol. Int. 25, 993-995[CrossRef][Medline] [Order article via Infotrieve]
39. Chen, Z. N., Liu, Y. F., and Yang, J. Z. (1989) Reports on Monoclonal Antibody 27, 33-36
40. Mensing, H., Albini, A., Krieg, T., Pontz, B. F., and Muller, P. K. (1984) Int. J. Cancer 33, 43-48[Medline] [Order article via Infotrieve]
41. Winegar, B. D., Kelly, R., and Lansman, J. B. (1991) J. Physiol. (Lond.) 97, 351-367
42. Denninger, J. W., and Marletta, M. A. (1999) Biochim. Biophys. Acta 1411, 334-350[Medline] [Order article via Infotrieve]
43. Biswas, C. (1982) Biochem. Biophys. Res. Commun. 109, 1026-1034[CrossRef][Medline] [Order article via Infotrieve]
44. Curran, S., and Murray, G. I. (2000) Eur. J. Cancer 36, 1621-1630
45. Jurasz, P., Sawicki, G., Duszyk, M., Sawicka, J., Miranda, C., Mayers, I., and Radomski, M. W. (2001) Cancer Res. 61, 376-382[Abstract/Free Full Text]
46. Kleiman, H. K., McGarvey, M. L., Hassell, J. R., Star, V. L., Cannon, F. B., Laurie, G. W., and Martin, G. R. (1986) Biochemistry 25, 312-318[CrossRef][Medline] [Order article via Infotrieve]
47. Sun, J. J., Zhou, X. D., Liu, Y. K., Tang, Z. Y., Sun, R. X., Zhao, Y., and Uemura, T. (2000) J. Cancer Res. Clin. Oncol. 126, 595-600[CrossRef][Medline] [Order article via Infotrieve]
48. Bauer, K. S., Cude, K. J., Dixon, S. C., Kruger, E. A., and Figg, W. D. (2000) J. Pharmacol. Exp. Ther. 292, 31-37[Abstract/Free Full Text]
49. Farias, E. F., Aguirre, Ghiso, J. A., Ladeda, V., and Bal de Kier Joffe, E. (1998) Int. J. Cancer 78, 727-734[CrossRef][Medline] [Order article via Infotrieve]
50. Kohn, E. C., Felder, C. C., Jacobs, W., Holmes, K. A., Day, A., Freer, R., and Liotta, L. A. (1994) Cancer Res. 54, 935-942[Abstract/Free Full Text]
51. Sun, J., and Hemler, M. E. (2001) Cancer Res. 61, 2276-2281[Abstract/Free Full Text]
52. Dalberg, K., Eriksson, E., Enberg, U., Kjellman, M., and Backdahl, M. (2000) World J. Surg. 24, 334-340[CrossRef][Medline] [Order article via Infotrieve]
53. Lokeshwar, B. L. (1999) Ann. N. Y. Acad. Sci. 878, 271-289[CrossRef][Medline] [Order article via Infotrieve]
54. George, S. J., Johnson, J. L., Angelini, G. D., and Jeremy, J. Y. (1997) Arterioscler. Thromb. Vasc. Biol. 17, 2500-2506[Abstract/Free Full Text]
55. Zeng, L., An, S., and Goetzl, E. J. (1996) J. Biol. Chem. 271, 27744-27750[Abstract/Free Full Text]
56. Lala, P. K. (1998) Cancer Metastasis Rev. 17, 1-6[CrossRef][Medline] [Order article via Infotrieve]
57. Sameshima, T., Nabeshima, K., Toole, B. P., Yokogami, K., Okada, Y., Goya, T., Koono, M., and Wakisaka, S. (2000) Int. J. Cancer 88, 21-27[CrossRef][Medline] [Order article via Infotrieve]
58. Zucker, S., Hymowitz, M., Rollo, E. E., Mann, R., Conner, C. E., Cao, J., Foda, H. D., Tompkins, D. C., and Toole, B. P. (2001) Am. J. Pathol. 158, 1921-1928[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
X.-Z. Ju, J.-M. Yang, X.-Y. Zhou, Z.-T. Li, and X.-H. Wu
EMMPRIN Expression as a Prognostic Factor in Radiotherapy of Cervical Cancer
Clin. Cancer Res., January 15, 2008; 14(2): 494 - 501.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
J. Xu, H.-Y. Xu, Q. Zhang, F. Song, J.-L. Jiang, X.-M. Yang, L. Mi, N. Wen, R. Tian, L. Wang, et al.
HAb18G/CD147 Functions in Invasion and Metastasis of Hepatocellular Carcinoma
Mol. Cancer Res., June 1, 2007; 5(6): 605 - 614.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
J. Tang, H.-w. Zhou, J.-l. Jiang, X.-m. Yang, Y. Li, H.-X. Zhang, Z.-n. Chen, and W.-p. Guo
{beta}ig-h3 Is Involved in the HAb18G/CD147-Mediated Metastasis Process in Human Hepatoma Cells
Experimental Biology and Medicine, March 1, 2007; 232(3): 344 - 352.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J.-M. Yang, P. O'Neill, W. Jin, R. Foty, D. J. Medina, Z. Xu, M. Lomas, G. M. Arndt, Y. Tang, M. Nakada, et al.
Extracellular Matrix Metalloproteinase Inducer (CD147) Confers Resistance of Breast Cancer Cells to Anoikis through Inhibition of Bim
J. Biol. Chem., April 7, 2006; 281(14): 9719 - 9727.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
W. Tang, S. B. Chang, and M. E. Hemler
Links between CD147 Function, Glycosylation, and Caveolin-1
Mol. Biol. Cell, September 1, 2004; 15(9): 4043 - 4050.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Tang and M. E. Hemler
Caveolin-1 Regulates Matrix Metalloproteinases-1 Induction and CD147/EMMPRIN Cell Surface Clustering
J. Biol. Chem., March 19, 2004; 279(12): 11112 - 11118.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
J.-M. Yang, Z. Xu, H. Wu, H. Zhu, X. Wu, and W. N. Hait
Overexpression of Extracellular Matrix Metalloproteinase Inducer in Multidrug Resistant Cancer Cells
Mol. Cancer Res., April 1, 2003; 1(6): 420 - 427.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/50/46870    most recent
M108291200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jiang, J. L.
Right arrow Articles by Chan, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jiang, J. L.
Right arrow Articles by Chan, H. C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement